HOME > TOP STORIES
TOP STORIES
-
BUSINESS Perspective on Takeda/Shire Deal - 1: Profits Delivered by On-Market Products More Important than Pipeline
May 29, 2018
-
REGULATORY Takeda’s Entyvio Up for MHLW Panel Review on June 8
May 28, 2018
-
BUSINESS 3 Generic Major Companies Maintain Double-Digit Growth in FY2017: Jiho Tally
May 28, 2018
-
REGULATORY MOF Pitching 2-Step Drug Price Tweaks in 2019 Tax Hike Year
May 25, 2018
-
ORGANIZATION Isao Teshirogi Elected New FPMAJ Chairman
May 25, 2018
-
REGULATORY PMDA, FDA Team Up to Help Developing Countries to Facilitate Pediatric Drug Development
May 24, 2018
-
BUSINESS Astellas Eyes 1 Trillion Yen Peak Sales with 6 Late-Stage Assets: Biz Plan
May 23, 2018
-
BUSINESS Hemlibra, MSD/Astellas’ DPP-4/SGLT2 Combo Hit Japan Market
May 23, 2018
-
BUSINESS Kyowa Kirin to Use Surrogate Endpoint in PIII Trial of Sakigake CKD Treatment; Application Could Come as Early as 2022
May 22, 2018
-
TRENDS Daiichi Sankyo Espha Sales Double as It Cashes In On Authorized Generic Boom
May 21, 2018
-
BUSINESS 10 Major Japan Drug Makers’ Sales Up 3.3%, but Decline Expected for FY2018 on Price Revision
May 18, 2018
-
REGULATORY Chuikyo Rep Frowns on Low Manufacturing Cost Disclosure, Says New Rule Might Need Revisiting
May 17, 2018
-
REGULATORY Pricing OK’ed for Hemlibra, Parmodia; Prevymis 1st in 3 Years to Get At-Launch Premium for Innovation
May 17, 2018
-
BUSINESS Eisai Chalks Up 1st Double-Digit Growth in 11 Years on Merck Deal, Global Brands
May 16, 2018
-
BUSINESS Velcade Sales Would Slide 50%, but Weber Stresses Takeda’s Strong Momentum
May 15, 2018
-
BUSINESS Latuda Use Patent Suit Could Wrap Up in December: Sumitomo Dainippon Chief
May 14, 2018
-
BUSINESS Sumitomo Dainippon’s Sales Hike 14.3% Buoyed by Latuda
May 14, 2018
-
BUSINESS Ono to Boost Oncology Reps to Prep for Opdivo Label Expansions
May 11, 2018
-
BUSINESS Takeda Confident It Can Reduce Debt Quickly after Shire Takeover: CEO
May 11, 2018
-
BUSINESS Mitsubishi Tanabe Logs Record Sales, but Profits Sag on Higher R&D/SGA Costs
May 10, 2018
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
